Oncogenuity

Oncogenuity is a biopharmaceutical company dedicated to the development and commercialization of ONCOlogues for the treatment of gene-driven cancers and coronaviruses. Oncogenuity's primary asset targets the KRAS mutation G12D. Oncogenuity is located in New York City and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO).